Search Details

Word: beecham (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

Sources--GOOD NEWS: Journal of the American Medical Association; American Association for Geriatric Psychiatry meeting; SmithKline Beecham Clinical Laboratories BAD NEWS: Journal of the American Medical Association; New England Journal of Medicine; American Journal of Epidemiology...

Author: /time Magazine | Title: Notebook: Mar. 17, 1997 | 3/17/1997 | See Source »

Introduced in the U.S. by SmithKline Beecham in 1977 and under patent protection for 17 years, Tagamet was the pioneer acid blocker. Worldwide it has earned the company a total of $14 billion and was the first drug ever to chalk up $1 billion in sales in a single year. But in the late 1980s, anticipating the worst when its Tagamet patent ran out in 1994, SmithKline began conducting clinical trials and seeking FDA approval of an over-the-counter version. The wisdom of that decision became evident when Tagamet sales plummeted from $600 million in 1993 to only...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

Both sides quickly complied, accepting the ruling philosophically and seemingly without rancor. "It's not unusual for one company to think the other's advertising is off base," says Jack Ziegler, president of North America SmithKline Beecham consumer health care. "We view Johnson & Johnson/Merck's advertising as inappropriate, as they view ours. Unfortunately this leads to lawsuits...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

...race to corner the heartburn market, Merck's Pepcid and SmithKline Beecham's Tagamet have the early lead. Both drugs boasted stellar records as anti-ulcer drugs in the prescription market and gained final U.S. approval for over-the-counter sales in April and June, respectively. Despite Zantac's late start, its popularity may enable it to overtake its rivals. Currently, it is the world's best-selling prescription drug. Analysts expect the three manufacturers together to spend some $300 million to tout their products...

Author: /time Magazine | Title: NEED A NEW DRUG? | 7/31/1995 | See Source »

Most vaccine production is carried out by five major pharmaceutical companies: Merck, Smith-Kline Beecham, Connaught, Merieux and Medeva. But according to Dennis Panicali, president and CEO of the Cambridgebased Therion Biologics Corporation, it's the small biotechnology firms which are experimenting with more novel techniques for producing vaccines...

Author: By Steven G. Dickstein, | Title: How to Make A Vaccine | 11/9/1993 | See Source »

First | Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next | Last